Clinical trials: Crohn Disease of Intestine
Intestinal Disease, Inflammatory Bowel Disease
Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease
The purpose of this study is to compare the clinical findings involving the small bowel obtained with the Capso Vision Video Capsule Device to those results obtained with the PillCam SB2.
- Conditions
- Intestinal Disease, Inflammatory Bowel Disease, Crohn Disease, Ulcer
- Trial name
- NCT01787825
- Testing
- PillCam SB2 capsule, CapsoCam SV-1
- Where
- 7 sites in United States, Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Capso Vision, Inc.
Inflammatory Disease, Drug Side Effect
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic…
- Conditions
- Inflammatory Disease, Drug Side Effect, Drug Use, Adverse Drug Event
- Trial name
- LOOK-UP (NCT06498167)
- Testing
- Upadacitinib
- Where
- 3 sites in Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto
Crohns Disease
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
- Trial name
- NCT01769755
- Testing
- PDA001
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Celularity Incorporated
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
- Trial name
- GUSTO-UK (NCT07242248)
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn's Disease
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).
- Trial name
- NCT01393626
- Testing
- CP-690,550
- Where
- 140 sites in United States, Australia and 16 more
- Volunteers
- 280 people
- Sponsor
- Pfizer
Crohn Disease
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
This study is design to explore the effect of GED-0301 on clinical and endoscopic outcome and to evaluate its safety in subjects with active Crohn's disease.
- Trial name
- NCT02367183
- Testing
- GED-0301
- Where
- 50 sites in United States, Australia and 3 more
- Volunteers
- 64 people
- Sponsor
- Celgene
Ulcerative Colitis, Crohn's Disease
Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population
The aim of the present study was to describe the incidence and prevalence of IBD in non Jewish Israel population
- Trial name
- NCT00815061
- Where
- Israel
- Sponsor
- Rabin Medical Center
Crohn's Disease
Psychology of Crohn's Disease
The purpose of this study is to determine whether emotional processing and somatic dissociation influence IBS-like symptoms in Crohn's Disease patients.
- Trial name
- NCT01573078
- Testing
- Questionnaire
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Crohn Disease
Effect of Biologic Therapy on Surgical Outcomes for Perforated Crohn's Patients
crohn's disease patients who present by intestinal perforation as the first presentation are hard to deal with. Surgical techniques as anastmosis or diversion stoma and active course of the disease may greatly affect the quality…
- Trial name
- NCT06511921
- Testing
- early biologic therapy, late biologic therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Zagazig University
Ulcerative Colitis, Crohn's Disease
Evaluation of Health Costs and Resource Utilization
Utilization of health resources in a testing based strategy versus an empiric dose escalation strategy to manage Crohn's disease and Ulcerative Colitis in subjects with loss of response to infliximab or adalimumab.
- Trial name
- Test-NoTest (NCT01960426)
- Testing
- Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Western Ontario, Canada
Inflammatory Bowel Disease, Ulcerative Colitis
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT02413047
- Testing
- Azathioprine, 6 mercaptopurine, Methotrexate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
Crohn Disease (CD)
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow…
- Trial name
- NCT07625293
- Testing
- DB-3Q
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Ulcerative Colitis, Crohn's Disease
Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases
The aim of this study is to test Eicosapentaenoic free fatty acid's effects on calprotectin levels in IBD patients in clinical remission.
- Trial name
- NCT02179372
- Testing
- Eicosapentaenoic acid
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Crohn Disease
Treg Immunotherapy in Crohn's Disease
Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut. Crohn's can affect any part of the gut, though the most common area affected is the end of the ileum (the last part of the small…
- Trial name
- TRIBUTE (NCT03185000)
- Testing
- TR004 (Treg immunotherapy)
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- King's College London
Inflammatory Bowel Diseases, Crohn Disease
Shared Decision Making in Paediatric Inflammatory Bowel Disease
The goal of this mixed-methods prospective cohort study is to assess the impact of shared decision-making (SDM) on newly diagnosed pediatric inflammatory bowel disease (IBD) patients and their families.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, IBD
- Trial name
- SDM-IBD (NCT05689892)
- Testing
- Decision Coach Sessions
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre
Crohn Disease (CD)
Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar
In a population of adult patients followed for Crohn's disease, who had previously agreed to replace Stelara® with a biosimilar of ustekinumab (Uzpruvo®) and were followed over a period of 12 months under usual medical practice…
- Trial name
- NCT07077681
- Where
- 11 sites in France
- Volunteers
- 246 people
- Sponsor
- EG Labo
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Crohn's Disease
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
OBJECTIVES: I. Evaluate the efficacy of chimeric monoclonal antibody (cA2) compared with placebo in closure of enterocutaneous fistulae in patients with Crohn's disease.
- Trial name
- NCT00004941
- Testing
- monoclonal antibody cA2
- Volunteers
- 94 people
- Sponsor
- FDA Office of Orphan Products Development
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1
Phase I Clinical Study of ZL-82 Tablets
ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3.
- Trial name
- NCT06055023
- Testing
- ZL-82 12.5mg, ZL-82 25mg, ZL-82 50mg
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.